We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Expert: Comparative Effectiveness Mandate Would Burden Drugmakers
Industry Expert: Comparative Effectiveness Mandate Would Burden Drugmakers
June 16, 2011
Mandating comparative effectiveness research (CER) for drug approvals as part of Prescription Drug User Fee Act (PDUFA) reauthorization is unnecessary, would yield ineffective data and would add a major hurdle to the development of new drugs, an industry expert says.